• 1
    Mueller NE, Grufferman S. Hodgkin lymphoma. In: Schottenfeld D, Fraumeni JF, Jr, eds. Cancer epidemiology and prevention, 3rd edn. New York: Oxford University Press, 2006. 87297.
  • 2
    Glaser SL, Lin RJ, Stewart SL, Ambinder RF, Jarrett RF, Brousset P, Pallesen G, Gulley ML, Khan G, O'Grady J, Hummel MH, Preciado MV, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 1997; 70: 37582.
  • 3
    Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 1989; 320: 5026.
  • 4
    Mueller N, Evans A, Harris NL, Comstock GW, Jellum E, Magnus K, Orentreich N, Polk BF, Vogelman J. Hodgkin's disease and Epstein-Barr virus: altered antibody pattern before diagnosis. N Engl J Med 1989; 320: 68995.
  • 5
    Hjalgrim H, Smedby KE, Rostgaard K, Molin D, Hamilton-Dutoit S, Chang ET, Ralfkiaer E, Sundström C, Adami H-O, Glimelius B, Melbye M. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res 2007; 67: 23828.
  • 6
    Gutensohn (Mueller) N, Cole P. Childhood social environment and Hodgkin's disease. N Engl J Med 1981; 304: 13540.
  • 7
    Mueller NE. Epstein-Barr virus and Hodgkin's disease: an epidemiologic paradox. Epstein-Barr Virus Rep 1997; 4: 12.
  • 8
    Gallagher A, Perry J, Shield L, Freeland J, MacKenzie J, Jarrett RF. Viruses and Hodgkin disease: no evidence of novel herpesviruses in non-EBV-associated lesions. Int J Cancer 2002; 101: 25964.
  • 9
    Kieff ED, Rickinson AB. Epstein-Barr virus and its replication. In: Knipe DM, Howley PM, eds. Fields virology, 5th edn., vol. 2. Philadelphia: Lippincott Williams & Wilkins, 2007. 260354.
  • 10
    Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, eds. Fields Virology, 5th edn., vol. 2. Philadelphia: Lippincott Williams & Wilkins, 2007. 2655700.
  • 11
    Henle W, Henle G, Andersson J, Ernberg I, Klein G, Horwitz CA, Marklund G, Rymo L, Wellinder C, Straus SE. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci USA 1987; 84: 5704.
  • 12
    Evans AS, Gutensohn (Mueller) N. A population-based case control study of EBV and other viral antibodies among persons with Hodgkin's disease and their siblings. Int J Cancer 1984; 34: 14957.
  • 13
    Lennette ET, Rymo L, Yadav M, Masucci G, Merk K, Timar L, Klein G. Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6. Eur J Cancer 1993; 29A: 15849.
  • 14
    Niederman JC, Evans AS. Epstein-Barr virus. In: Evans AS, Kaslow RA, eds. Viral infections of humans. Epidemiology and control, 4th edn. New York, NY: Plenum Medical Book Company, 1997. 25383.
  • 15
    Wagner HJ, Hornef M, Middeldorp J, Kirchner H. Characteristics of viral protein expression by Epstein-Barr virus-infected B cells in peripheral blood of patients with infectious mononucleosis. Clin Diagn Lab Immunol 1995; 2: 6969.
  • 16
    Prang NS, Hornef MW, Jäger M, Wagner HJ, Wolf H, Schwarzmann FM. Lytic replication of Epstein-Barr virus in the peripheral blood: analysis of viral gene expression in B lymphocytes during infectious mononucleosis and in the normal carrier state. Blood 1997; 89: 166577.
  • 17
    Niedobitek G, Agathanggelou A, Herbst H, Whitehead L, Wright DH, Young LS. Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. J Pathol 1997; 182: 1519.
  • 18
    Romagnani S. T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol 2000; 85: 918.
  • 19
    Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Ann Rev Microbiol 2000; 54: 1948.
  • 20
    Cozen W, Gill PS, Ingles SA, Masood R, Martínez-Maza O, Cockburn MG, Gauderman WJ, Pike MC, Bernstein L, Nathwani BN, Salam MT, Danley KL, et al. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood 2004; 103: 321621.
  • 21
    Cozen W, Gill PS, Salam MT, Nieters A, Masood R, Cockburn MG, Gauderman WJ, Martínez-Maza O, Nathwani BN, Pike MC, Van Den Berg DJ, Hamilton AS, et al. Interleukin-2, interleukin-12, and interferon-γ levels and risk of young adult Hodgkin lymphoma. Blood 2008; 111: 337782.
  • 22
    Seigneurin JM, Lavoue MF, Genoulaz O, Bornkamm GW, Lenoir GM. Antibody response against the Epstein-Barr virus-coded nuclear antigen 2 (EBNA 2) in different groups of individuals. Int J Cancer 1987; 40: 34953.
  • 23
    Winkelspecht B, Grässer F, Pees HW, Mueller-Lantzsch N. Anti-EBNA 1/anti-EBNA 2 ratio decreases significantly in patients with progression of HIV infection. Arch Virol 1996; 141: 85764.
  • 24
    Pedneault L, Lapointe N, Alfieri C, Ghadirian P, Carpentier L, Samson J, Joncas J. Antibody responses to two Epstein-Barr virus (EBV) nuclear antigens (EBNA-1 and EBNA-2) during EBV primary infection in children born to mothers infected with human immunodeficiency virus [notes]. Clin Infect Dis 1996; 23: 8068.
  • 25
    Levin LI, Lennette ET, Ambinder RF, Chang ET, Rubertone M, Mueller NE. Prediagnosis Epstein-Barr virus serologic patterns in relation to the molecular status of Hodgkin's lymphoma in young adults [abstract B62]. In: Program and abstracts of the American Association for Cancer Research International Conference on Molecular and Genetic Epidemiology of Cancer (Waikoloa, Hawaii). Philadelphia: American Association for Cancer Research, 2003.
  • 26
    Chang ET, Zheng T, Lennette ET, Weir EG, Borowitz M, Mann RB, Spiegelmann D, Mueller NE. Heterogeneity of risk factors and antibody profiles in Epstein-Barr virus genome-positive and -negative Hodgkin lymphoma. J Infect Dis 2004; 189: 227181.